Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
B001
- Development stage
- Phase 3
- Lead developer
- Shanghai Pharmaceuticals
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous (based On Standard Administration Of Monoclonal Antibodies And Available Trial Data)[3][5]
01
Overview
B001 is a recombinant humanized anti-CD20 monoclonal antibody developed by Shanghai Pharmaceuticals. It is designed to target the CD20 antigen on B-lymphocytes and acts primarily through antibody-dependent cell cytotoxicity. The drug has been investigated for immune system diseases such as neuromyelitis optica, multiple sclerosis, and certain cancers including non-Hodgkin's lymphoma. Its development status varies by indication but has reached up to phase II/III clinical trials in neuromyelitis optica and phase I in non-Hodgkin's lymphoma. The highest overall R&D status for the drug is discontinued[1][5].
- Other names
- anti-CD20 humanized monoclonal antibodyanti-CD-20 humanized monoclonal antibodyanti-CD 20 humanized monoclonal antibodyanti-CD20 humanized monoclonal antibody injectionanti-CD-20 humanized monoclonal antibody injectionanti-CD 20 humanized monoclonal antibody injection
02
Targets
Beyond the preview
Go deeper on B001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on B001.